Treating peripheral vascular disease. Migraine therapy Flashcards Preview

pharma final > Treating peripheral vascular disease. Migraine therapy > Flashcards

Flashcards in Treating peripheral vascular disease. Migraine therapy Deck (8)
Loading flashcards...
1
Q

Mechanism of the drugs that treat peripheral vascular disease

A

Vasodilation

Rheological effect - RBC modification

Platelet inhibition - aggregation inhibitors.

2
Q

Peripheral vascular diseases listed on the elearning

A
  • (3Ns, B3)
    Naftidrofuryl
    Nicergoline
    Niacin (B3)

Cinnarizine and Flunarizine

Vinpocetine
Pentoxifylline

Bencyclane

3
Q

Naftidrofuryl

A

increases peripheral circulation

SEs: Arrythmia, hypotension, angina

4
Q

Nicergoline

A

ErGOt derivative, but nicer :D

alpha1 inhibition
platelet inhibition
increases Dopamine in the brain.

Used for peripheral vasc. diseases and sometimes in dementia or cerebral casvular disease.

5
Q

Cinnarizine and Flunarizine

A
CCBs,
inhibit: 
Ca channels,
Platelet aggregation
RBC rigidity
Histamine receptors

SEs: Depression, sedation

6
Q

Pentoxifylline

A

Methylxanthine derivative, nonspecific PDE inhibitor.

inhibits platelet aggregation and decreases RBC blood viscocity.

for Atherosclerotic and Diabetic PVD.
claudication
sickle cell anemia

Orally admined, 
SEs: 
GI upset, tachycardia, 
angina
flushing
7
Q

Niacin

A

Decreases VLDL and LDL levels, (decreasing triglycerides)
Mild increase in HDL, most effective HDL increaser.

Rx:
Atherosclrotic PVD
Vasospastic PVD

SE:
LIVER damage, possibly severe. Liver monitoring is manditory.
flushing - caused by prostaglandins, limited by NSAID pretreatment
Hypotension
Tachydcardia
Hyperglycemia
Hyperuricemia and Gout - Allopurinol.

8
Q

Ones not listed on the elearning

A

Amlodipine and the dihydropyridine CCBs are 1st line for Raynauds

Cilostazol and Dipyridamole - PDE inhibitors, treat symptoms of PAD. inhibit platelet aggregation and cause arteriolar vasodilation.

Clopidogrel, Prasugrel, Ticagrelor, and Ticlodipine ADP receptor P2Y12 inhibitors.
-prophylaxis to decrease the associated MI risk.

Statins are indicated in PAD.
-Decrease atherosclerosis and MI risk.

Decks in pharma final Class (42):